Literature DB >> 17552031

Hepatitis C virus-related lymphoproliferative disorders: an overview.

Anna-Linda Zignego1, Carlo Giannini, Clodoveo Ferri.   

Abstract

Hepatitis C virus (HCV) is a global health problem affecting 3% of the world's population (about 180 million) and a cause of both hepatic and extrahepatic diseases. B-cell lymphoproliferative disorders, whose prototype is mixed cryoglobulinemia, represent the most closely related as well as the most investigated HCV-related extrahepatic disorder. The association between extrahepatic (lymphoma) as well as hepatic malignancies (hepatocellular carcinoma) has justified the inclusion of HCV among human cancer viruses. HCV-associated manifestations also include porphyria cutanea tarda, lichen planus, nephropathies, thyreopathies, sicca syndrome, idiopathic pulmonary fibrosis, diabetes, chronic polyarthritis, sexual dysfunctions, cardiopathy/atherosclerosis, and psychopathological disorders. A pathogenetic link between HCV virus and some lymphoproliferative disorders was confirmed by their responsiveness to antiviral therapy, which is now considered the first choice treatment. The aim of the present paper is to provide an overview of extrahepatic manifestations of HCV infection with particular attention to B-cell lymphoproliferative disorders. Available pathogenetic hypotheses and suggestions about the most appropriate, currently available, therapeutic approaches will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552031      PMCID: PMC4146766          DOI: 10.3748/wjg.v13.i17.2467

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  139 in total

1.  Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment.

Authors:  Carlo Giannini; Francesca Giannelli; Anna Linda Zignego
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

Review 2.  Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach.

Authors:  A L Zignego; C Ferri; S A Pileri; P Caini; F B Bianchi
Journal:  Dig Liver Dis       Date:  2006-08-01       Impact factor: 4.088

3.  Non-Hodgkin's lymphoma: possible role of hepatitis C virus.

Authors:  C Ferri; L La Civita; F Caracciolo; A L Zignego
Journal:  JAMA       Date:  1994-08-03       Impact factor: 56.272

4.  Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia.

Authors:  G Pozzato; C Mazzaro; M Crovatto; M L Modolo; S Ceselli; G Mazzi; S Sulfaro; F Franzin; P Tulissi; M Moretti
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

5.  Hepatitis C virus infection in patients with non-Hodgkin's lymphoma.

Authors:  C Ferri; F Caracciolo; A L Zignego; L La Civita; M Monti; G Longombardo; F Lombardini; F Greco; E Capochiani; A Mazzoni
Journal:  Br J Haematol       Date:  1994-10       Impact factor: 6.998

6.  Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes.

Authors:  J M Pawlotsky; F Roudot-Thoraval; P Simmonds; J Mellor; M B Ben Yahia; C André; M C Voisin; L Intrator; E S Zafrani; J Duval; D Dhumeaux
Journal:  Ann Intern Med       Date:  1995-02-01       Impact factor: 25.391

7.  Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage.

Authors:  F Lunel; L Musset; P Cacoub; L Frangeul; P Cresta; M Perrin; P Grippon; C Hoang; D Valla; J C Piette
Journal:  Gastroenterology       Date:  1994-05       Impact factor: 22.682

Review 8.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

9.  Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study.

Authors:  F Dammacco; D Sansonno; J H Han; V Shyamala; V Cornacchiulo; A R Iacobelli; G Lauletta; R Rizzi
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

10.  Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia.

Authors:  C Mazzaro; G Pozzato; M Moretti; M Crovatto; M L Modolo; G Mazzi; G Santini
Journal:  Haematologica       Date:  1994 Jul-Aug       Impact factor: 9.941

View more
  32 in total

Review 1.  Hepatitis viruses and non-Hodgkin's lymphoma: A review.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Rudragoud S Policegoudra; Hemant K Gogoi; Lokendra Singh
Journal:  World J Virol       Date:  2012-12-12

2.  An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon.

Authors:  Endri Mauro; Mariangela Pedata; Anna Ermacora; Cesare Mazzaro
Journal:  Blood Transfus       Date:  2011-07-18       Impact factor: 3.443

3.  The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis.

Authors:  Amal Abdul-Hafez; Tarek Mohamed; Hanan Omar; Mohamed Shemis; Bruce D Uhal
Journal:  J Lung Pulm Respir Res       Date:  2018-02-27

4.  Cryoglobulinemia in elderly patients with HCV-related chronic hepatitis.

Authors:  Francesco Giuseppe Foschi; Anna Chiara Dall'aglio; Arianna Lanzi; Giorgio Marano; Sara Savini; Pietro Andreone; Mauro Bernardi; Giuseppe Francesco Stefanini
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-04-06

5.  Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.

Authors:  Oluwaseun Falade-Nwulia; Mark S Sulkowski
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

Review 6.  DUBbing Down Translation: The Functional Interaction of Deubiquitinases with the Translational Machinery.

Authors:  Bandish B Kapadia; Ronald B Gartenhaus
Journal:  Mol Cancer Ther       Date:  2019-09       Impact factor: 6.261

7.  Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.

Authors:  Annunziata Faustini; Paola Colais; Emanuele Fabrizi; Anna Maria Bargagli; Marina Davoli; Domenico Di Lallo; Anteo Di Napoli; Patrizio Pezzotti; Chiara Sorge; Rita Grillo; Carla Maresca; Olga Recchia; Carlo A Perucci
Journal:  BMC Infect Dis       Date:  2010-04-19       Impact factor: 3.090

8.  Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Marialina Tornesello; Maria Napolitano; Debora Martorelli; Giuseppe Castello; Gerardo Beneduce; Amalia De Renzo; Oreste Perrella; Luca Romagnoli; Vitor Sousa; Valli De Re; Riccardo Dolcetti; Franco M Buonaguro
Journal:  J Transl Med       Date:  2010-02-19       Impact factor: 5.531

Review 9.  The hepatitis C virus infection as a systemic disease.

Authors:  Anna Linda Zignego; Laura Gragnani; Carlo Giannini; Giacomo Laffi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

10.  Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients.

Authors:  Diana V Stefanova-Petrova; Anelia H Tzvetanska; Elisaveta J Naumova; Anastasia P Mihailova; Evgenii A Hadjiev; Rumiana P Dikova; Mircho I Vukov; Konstantin G Tchernev
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.